You just read:

Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Apr 01, 2011, 10:00 ET